Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'
Veeva Systems (NYSE: VEEV) and Boehringer Ingelheim have successfully launched the 'One Medicine Platform' powered by Veeva Development Cloud, marking a significant milestone in their collaboration announced in March 2022. The platform unifies data and processes across clinical, regulatory, and quality functions.
As one of the top 20 biopharma companies, Boehringer Ingelheim is leveraging this unified platform to streamline product development, optimize trial efficiency, and enhance collaboration with research sites. The implementation enables seamless data connectivity across functions, aiming to accelerate the delivery of new treatments for currently incurable diseases.
The Veeva Development Cloud serves as the technology foundation, integrating clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.
Veeva Systems (NYSE: VEEV) e Boehringer Ingelheim hanno lanciato con successo la 'One Medicine Platform', alimentata dal Veeva Development Cloud, segnando un traguardo significativo nella loro collaborazione annunciata a marzo 2022. La piattaforma unifica dati e processi attraverso le funzioni cliniche, regolatorie e di qualità.
Come una delle prime 20 aziende biopharma, Boehringer Ingelheim sta sfruttando questa piattaforma unificata per semplificare lo sviluppo dei prodotti, ottimizzare l'efficienza degli studi e migliorare la collaborazione con i siti di ricerca. L'implementazione consente una connettività dei dati senza soluzione di continuità tra le funzioni, con l'obiettivo di accelerare la consegna di nuovi trattamenti per malattie attualmente incurabili.
Il Veeva Development Cloud funge da fondamento tecnologico, integrando applicazioni cliniche, di qualità, regolatorie e di sicurezza per semplificare i processi aziendali end-to-end e garantire l'eccellenza dei processi.
Veeva Systems (NYSE: VEEV) y Boehringer Ingelheim han lanzado con éxito la 'One Medicine Platform', impulsada por Veeva Development Cloud, marcando un hito significativo en su colaboración anunciada en marzo de 2022. La plataforma unifica datos y procesos en las funciones clínicas, regulatorias y de calidad.
Como una de las 20 principales empresas biofarmacéuticas, Boehringer Ingelheim está aprovechando esta plataforma unificada para agilizar el desarrollo de productos, optimizar la eficiencia de los ensayos y mejorar la colaboración con los sitios de investigación. La implementación permite una conectividad de datos sin interrupciones entre funciones, con el objetivo de acelerar la entrega de nuevos tratamientos para enfermedades actualmente incurables.
El Veeva Development Cloud sirve como base tecnológica, integrando aplicaciones clínicas, de calidad, regulatorias y de seguridad para simplificar los procesos comerciales de extremo a extremo y brindar excelencia en los procesos.
Veeva Systems (NYSE: VEEV)와 Boehringer Ingelheim은 Veeva Development Cloud 기반의 'One Medicine Platform'을 성공적으로 출시하여 2022년 3월 발표된 협력의 중요한 이정표를 세웠습니다. 이 플랫폼은 임상, 규제 및 품질 기능 전반에 걸쳐 데이터와 프로세스를 통합합니다.
상위 20개 바이오 제약 회사 중 하나인 Boehringer Ingelheim은 이 통합 플랫폼을 활용하여 제품 개발을 간소화하고, 시험 효율성을 최적화하며, 연구 사이트와의 협업을 강화하고 있습니다. 구현은 기능 간의 원활한 데이터 연결을 가능하게 하여 현재 치료할 수 없는 질병에 대한 새로운 치료법의 제공을 가속화하는 것을 목표로 합니다.
Veeva Development Cloud는 기술 기반 역할을 하며, 임상, 품질, 규제 및 안전 애플리케이션을 통합하여 엔드 투 엔드 비즈니스 프로세스를 단순화하고 프로세스 우수성을 제공합니다.
Veeva Systems (NYSE: VEEV) et Boehringer Ingelheim ont lancé avec succès la 'One Medicine Platform', alimentée par Veeva Development Cloud, marquant une étape significative dans leur collaboration annoncée en mars 2022. La plateforme unifie les données et les processus à travers les fonctions cliniques, réglementaires et de qualité.
En tant que l'une des 20 principales entreprises biopharmaceutiques, Boehringer Ingelheim utilise cette plateforme unifiée pour rationaliser le développement de produits, optimiser l'efficacité des essais et améliorer la collaboration avec les sites de recherche. La mise en œuvre permet une connectivité des données sans faille entre les fonctions, visant à accélérer la livraison de nouveaux traitements pour des maladies actuellement incurables.
Le Veeva Development Cloud sert de fondation technologique, intégrant des applications cliniques, de qualité, réglementaires et de sécurité pour simplifier les processus commerciaux de bout en bout et garantir l'excellence des processus.
Veeva Systems (NYSE: VEEV) und Boehringer Ingelheim haben erfolgreich die 'One Medicine Platform' eingeführt, die auf der Veeva Development Cloud basiert, und damit einen bedeutenden Meilenstein in ihrer im März 2022 angekündigten Zusammenarbeit erreicht. Die Plattform vereint Daten und Prozesse in den klinischen, regulatorischen und Qualitätsfunktionen.
Als eines der 20 führenden Biopharma-Unternehmen nutzt Boehringer Ingelheim diese einheitliche Plattform, um die Produktentwicklung zu optimieren, die Effizienz von Studien zu steigern und die Zusammenarbeit mit Forschungsstandorten zu verbessern. Die Implementierung ermöglicht eine nahtlose Datenverbindung zwischen den Funktionen, mit dem Ziel, die Bereitstellung neuer Behandlungen für derzeit unheilbare Krankheiten zu beschleunigen.
Die Veeva Development Cloud dient als technologische Grundlage, die klinische, Qualitäts-, Regulierungs- und Sicherheitsanwendungen integriert, um die End-to-End-Geschäftsprozesse zu vereinfachen und Prozessqualität zu gewährleisten.
- Strategic partnership with top 20 biopharma company Boehringer Ingelheim
- Successful implementation of comprehensive Development Cloud platform
- Expansion of Veeva's presence in clinical trial technology market
- None.
Insights
This partnership announcement represents a significant milestone for Veeva Systems, as Boehringer Ingelheim - a top 20 global biopharma company - has successfully implemented and launched their "One Medicine Platform" powered by Veeva Development Cloud. What makes this particularly noteworthy is that it represents the successful completion of a complex enterprise implementation first announced in March 2022, demonstrating Veeva's ability to execute on multi-year, enterprise-scale digital transformation initiatives.
The implementation connects three critical pharmaceutical functions - clinical, regulatory, and quality - into a unified data platform. This integration approach directly addresses one of the pharmaceutical industry's biggest technical challenges: siloed data and disconnected processes that slow drug development.
From a technical perspective, this implementation validates Veeva's platform architecture and integration capabilities. The public endorsement from Boehringer's head of learning specifically highlighting "speed, efficiency, and compliance" benefits provides powerful third-party validation of Veeva's value proposition in streamlining complex regulatory processes.
This reference implementation at a global pharma leader strengthens Veeva's market position and could accelerate adoption among other large pharmaceutical companies evaluating similar digital transformation initiatives. The successful delivery of the One Medicine Platform after three years demonstrates Veeva's capabilities in managing complex implementation cycles typical in regulated industries.
Boehringer Ingelheim's implementation of Veeva Development Cloud represents a strategic win for Veeva in the competitive life sciences technology market. As one of the world's largest private pharmaceutical companies with
The unified platform approach directly addresses a critical industry pain point - the fragmented technology landscape that hampers drug development speed. By connecting clinical, regulatory, and quality processes, the One Medicine Platform enables Boehringer to potentially accelerate time-to-market for treatments targeting unmet medical needs.
What's particularly valuable for Veeva is that this implementation crosses multiple functional domains, suggesting a comprehensive enterprise deployment rather than a point solution. Enterprise-wide implementations typically represent larger contract values and deeper customer relationships with higher switching costs, contributing to Veeva's stable recurring revenue model.
For pharmaceutical companies under immense pressure to improve R&D productivity and accelerate time-to-market, this successful implementation offers a potential blueprint for digital transformation. While financial terms weren't disclosed, the strategic value for Veeva extends beyond immediate revenue impact - it positions their Development Cloud as a proven solution for innovation-focused pharmaceutical companies seeking to modernize clinical trial operations and streamline regulatory processes.
Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases
INGELHEIM,
"Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance."
"By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."
Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.
Additional Information
For more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloud
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact: | |
Deivis Mercado | Jeremy Whittaker |
View original content to download multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-partners-with-veeva-to-launch-one-medicine-platform-302397880.html
SOURCE Veeva Systems
FAQ
What is the One Medicine Platform launched by Boehringer Ingelheim and Veeva (VEEV)?
How does the Veeva (VEEV) Development Cloud benefit clinical trials?
When did Boehringer Ingelheim and Veeva (VEEV) first announce their One Medicine collaboration?
What are the key components integrated in Veeva's (VEEV) Development Cloud platform?
